GoAI
Get started
Zymeworks Inc. logo

Zymeworks Inc.

ZYME

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$27.665

−$0.995 · -3.47%

Aug 24, 10:18 AM ET

ZYME company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

53

Neutral

Sentiment

62

Bullish

Risk resilience

58

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Kenneth H. Galbraith
Listed since
Apr 28, 2017
Employees
231

Market position

Volume
159.85K
0.26× average
Average volume
609.02K
Average daily volume
Market cap
2.04B USD
Beta
1.15
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.96B USD
P/E (TTM)
-13.7×
P/B (TTM)
25.14×
P/S (TTM)
54.84×
EV / EBITDA
-28.56×
Earnings yield
-4.09%
Free cash flow yield
-1.74%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
87.78%
Operating margin
-418.99%
Net margin
-404.00%
Return on equity
-30.22%
Return on assets
-23.41%
Return on invested capital
-30.08%

Financial health

Debt / equity
3.34×
Current ratio
5.52×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends191%-172%-536%-899%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: -88.11%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -808.22%Operating margin, FY2022: 31.64%Operating margin, FY2023: -181.62%Operating margin, FY2024: -179.69%Operating margin, FY2025: -87.33%Net margin, FY2021: -794.01%Net margin, FY2022: 30.14%Net margin, FY2023: -156.13%Net margin, FY2024: -160.80%Net margin, FY2025: -76.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 -88.11%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -808.22%. Operating margin FY2022 31.64%. Operating margin FY2023 -181.62%. Operating margin FY2024 -179.69%. Operating margin FY2025 -87.33%. Net margin FY2021 -794.01%. Net margin FY2022 30.14%. Net margin FY2023 -156.13%. Net margin FY2024 -160.80%. Net margin FY2025 -76.56%.

Income trends

Revenue

105.97M USD+38.87%

Operating income

−92.54M USD+32.51%

Net income

−81.13M USD+33.88%
Income trends across reported periods475.29M USD224.05M USD−27.2M USD−278.44M USDRevenue, FY2021: 26.68M USDRevenue, FY2022: 412.48M USDRevenue, FY2023: 76.01M USDRevenue, FY2024: 76.3M USDRevenue, FY2025: 105.97M USDOperating income, FY2021: −215.63M USDOperating income, FY2022: 130.53M USDOperating income, FY2023: −138.05M USDOperating income, FY2024: −137.11M USDOperating income, FY2025: −92.54M USDNet income, FY2021: −211.84M USDNet income, FY2022: 124.34M USDNet income, FY2023: −118.67M USDNet income, FY2024: −122.7M USDNet income, FY2025: −81.13M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 26.68M USD. Revenue FY2022 412.48M USD. Revenue FY2023 76.01M USD. Revenue FY2024 76.3M USD. Revenue FY2025 105.97M USD. Operating income FY2021 −215.63M USD. Operating income FY2022 130.53M USD. Operating income FY2023 −138.05M USD. Operating income FY2024 −137.11M USD. Operating income FY2025 −92.54M USD. Net income FY2021 −211.84M USD. Net income FY2022 124.34M USD. Net income FY2023 −118.67M USD. Net income FY2024 −122.7M USD. Net income FY2025 −81.13M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue105.97M USD76.3M USD76.01M USD412.48M USD26.68M USD
Cost of goods sold——142.99M USD——
Gross profit105.97M USD76.3M USD−66.98M USD412.48M USD26.68M USD
Research and development137M USD134.62M USD143.62M USD208.6M USD199.75M USD
Selling, general, and administrative61.5M USD61.5M USD70.4M USD73.4M USD42.6M USD
Operating expenses198.5M USD213.41M USD71.08M USD281.95M USD242.31M USD
Interest income13.35M USD19.94M USD19.71M USD3.6M USD1.97M USD
Depreciation and amortization11.11M USD11.19M USD17.31M USD12M USD9.58M USD
Operating income−92.54M USD−137.11M USD−138.05M USD130.53M USD−215.63M USD
Net income−81.13M USD−122.7M USD−118.67M USD124.34M USD−211.84M USD

Company facts updated Aug 24, 2026.

ZYME peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ZYME

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
33.9M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.68-0.43%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
33.1M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.87-0.36%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
15.01M
Weight
0.14%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$211.1-1.15%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
12.44M
Weight
0.08%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.55-0.99%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
5.79M
Weight
0.03%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.76-0.40%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
5.43M
Weight
0.03%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$82.85-0.20%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
4.43M
Weight
0.06%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.97610.00%
Tema Oncology ETF logoTema Oncology ETFCANC
Market value
3.15M
Weight
1.46%
AUM
215.38M USD
Expense ratio
0.99%
Price / 1D
$43.98-1.38%

Continue in GoAI

Research ZYME

research.disclaimer